100年&counting:アルツハイマー病を克服する見通し
Erik D Roberson1, Lennart Mucke
1Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94158, USA.
Science (New York, N.Y.)
|November 4, 2006
まとめ
アルツハイマー病 (AD) は,現在の治療法にもかかわらず,壊滅的な状態です. アミロイドベータ,タウ,および神経の脆弱性を標的とする有望な新しい治療法は臨床試験中であり,アルツハイマー病の治療法の改善への希望を提供します.
科学分野:
- 神経科学は神経科学である.
- ゲロントロジーはゲロントロジーの学科です.
- 薬理学 薬理学とは
背景:
- アルツハイマー病 (AD) は1世紀前から知られていましたが,今でも記憶喪失と死亡の主な原因です.
- 現在のAD薬の有効性は限られており,新しい治療戦略の緊急の必要性を強調しています.
- アルツハイマー病の罹患率は,今後数十年で著しく増加すると予測されています.
研究 の 目的:
- 臨床開発におけるアルツハイマー病の治療法の現在の状況を見直す.
- AD治療の新たな治療目標と戦略を強調する.
- アルツハイマー病に対するより効果的な介入の開発の緊急性を強調する.
主な方法:
- アルツハイマー病の治療のための進行中の臨床試験のレビュー.
- アミロイドベータ,タウ,アポリポプロテインEを含むADの病原性に関する新興研究の分析.
- 神経細胞の脆弱性,そして老化とADの関連性に関する新しい洞察の探求.
主要な成果:
- 病原性アミロイドベータペプチドを標的とした複数の治療戦略が臨床試験中です.
- 脆弱なニューロンを退化から保護するためのアプローチは調査中です.
- 新興戦略は,老化に関連する要因とともに,アポリポタンパク質Eとタウのコパトジェニックな役割に焦点を当てています.
結論:
- アルツハイマー病の治療薬のパイプラインは,多様な,メカニズムベースのアプローチで拡大しています.
- アミロイドベータ,タウ,および神経の脆弱性をターゲットにすることは,将来のAD治療のための有望な経路を提供します.
- 効果的なアルツハイマー病の治療法の開発を加速することは,この病気の世界的な負担が増加しているため,非常に重要です.
さらに関連する動画
09:00Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain
Published on: April 28, 2022
09:47DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
関連する概念動画
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...